Status:
ACTIVE_NOT_RECRUITING
Use of Belatacept to Delay Tacrolimus Initiation in Kidney Transplant Patients with Delayed Graft Function
Lead Sponsor:
Methodist Health System
Conditions:
Use of Belatacept in Kidney Transplant Patients
Eligibility:
All Genders
18-85 years
Brief Summary
Evaluate the impact of one dose of belatacept in patients with Delayed Graft Function(DGF) on their time to renal recovery and corresponding rates of patient and graft survival, rejection, and inciden...
Detailed Description
Evaluate the impact of one dose of belatacept in patients with DGF on their time to renal recovery and corresponding rates of patient and graft survival, rejection, and incidence of BK virus, EBV and/...
Eligibility Criteria
Inclusion
- Age ≥18 years
- Received living or deceased donor kidney transplant during study period
- Documented DGF
Exclusion
- Multiple organ transplant
- Recipients with acute rejection present on first biopsy evaluation before first belatacept dose
- Recipients with a first dose of belatacept after index discharge or tacrolimus initiation
Key Trial Info
Start Date :
August 22 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 22 2025
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT06091995
Start Date
August 22 2022
End Date
August 22 2025
Last Update
November 20 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Methodist Dallas Medical Center
Dallas, Texas, United States, 75203